Company ProfilePremium

AnteoTech Limited

Company Profile Analysis

Ticker: ADO.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
AnteoTech Limited - Company showcase

Year Founded & Workforce

1995

40 Employees

AnteoTech Limited logo

AnteoTech Limited Employee Contacts

5 verified contactsNames, job titles, seniority and locations

View Employee Contacts

AnteoTech Limited Overview

MetricFY2025FY2026
Employee benefits expense incl. share-based payments (A$m)5.373.79
Salaries and fees (A$m)4.312.95
Superannuation (A$m)0.410.32

Headcount itself is not disclosed. The table below uses total employee benefits expense (A$m) as a proxy (source: Appendix 4E FY2026, Note 7).

AnteoTech is a Brisbane-based, pre-scale specialty chemicals and advanced-materials company. Its business is built on a single proprietary surface-chemistry platform based on metal-polymer coordination bonding ("nanoglue"). The company sells that platform into two very different markets:

Life Sciences (LS): in-vitro diagnostics, through the AnteoBind™ and AnteoBind™ NXT antibody-immobilisation reagents.

Advanced Battery Technologies (ABT): lithium-ion battery materials, through:

  • the Anteo X® silicon-anode cross-linker;

  • the Anteo S™ separator cross-linker;

  • the Anteo C current-collector primer;

  • the jointly developed SiMRAX product;

  • the Ultranode™ family of high-silicon anode formulations (Ultranode X, 70 and 95).

Revenue remains very small: A$0.47m in FY2026. It is concentrated in one customer, believed to be the Serum Institute of India under a five-year take-or-pay contract, which accounted for 59% of revenue.

The business is funded by equity raisings and Australian R&D tax incentives. After raising about A$13.8m in FY2026, it holds A$11.2m in cash and term deposits and has no bank debt.

Management describes the model as capital-light and partnership-driven, and calls FY2027 the "sales conversion" year. Investment value depends on converting technical validations into recurring commercial orders, in particular:

  • Ultranode 95 for drones and eVTOL;

  • CLIA diagnostics partnerships.


What the company does

AnteoTech develops and sells chemical reagents and material formulations based on its proprietary coordination-chemistry platform. The chemistry forms multiple metal-ligand bonds between a surface (polymer, metal, silica or silicon particle) and a target molecule or particle.

In diagnostics, this attaches antibodies and proteins to test surfaces with controlled orientation and stability. Examples of those surfaces are lateral-flow membranes, ELISA plates, CLIA magnetic beads and biosensors.

In batteries, the same chemistry acts as:

  • a cross-linker that holds silicon-rich anodes together through the large volume expansion of silicon during cycling;

  • a binder for ceramic coatings on separators;

  • an adhesion primer on current-collector foils.

The company's own description

The company describes itself in its ASX boilerplate (2026) as a supplier of chemicals and advanced material solutions to the lithium-ion battery and life-sciences markets. It says it uses its binding-chemistry platform technology to develop and commercialise solutions for a global customer base.

The FY2026 Appendix 4E (Note 4) states that the Group has one operating segment: "the development and commercialisation of AnteoTech's intellectual property and advanced chemicals and materials technologies". It adds that the ABT and LS businesses share common costs and that discrete financial information is not prepared for them.

Independent characterisation

EraApproximate periodDescription
Diagnostics product company2015–2017Owned DIAsource ImmunoAssays (Belgium)
Platform-technology developer2018–2024Life sciences, COVID-19 rapid antigen test development, energy materials
Commercialisation-focused ingredient and formulation supplierJune 2025 onwardStrategic Review; emphasis on standardised, market-ready products sold through partners and distributors

AnteoTech is best understood as an early-commercial, platform-IP company. Its revenue scale is that of a micro-cap ingredient supplier, but its cost base is that of an R&D organisation. FY2026 revenue from customers was A$467,589, against cash operating expenses of A$6.4–6.9m.

R&D tax incentive refunds of about A$2.4–2.6m a year fund roughly a third of the expense base. The rest has historically come from equity: shareholders have contributed A$116.8m in total, against accumulated losses of A$111.6m.

The company has moved through three strategic eras:

Business model and revenue model

Revenue typeFY2025 (AUD)FY2026 (AUD)Share of FY2026 revenue (%)Character
Product sales885,415402,99486.2Reagent and material sales: AnteoBind/NXT to diagnostics makers; ABT samples and early orders
Licence fees and royalties30,96300.0Legacy licensing
Contract services52,50064,59513.8Paid development programmes, e.g. A$64,500 CLIA programme with a global life-sciences company
Total revenue from customers968,878467,589100.0—

The revenue mix below is based on the revenue note in the Appendix 4E FY2026 (Note 5).

There is no subscription revenue. Licensing is now immaterial. The strategic intent, set out in the June 2025 Strategic Review, is to move away from bespoke R&D toward standardised product sales and joint-development agreements (JDAs) that lead to supply contracts.

Value-chain position

AnteoTech sits at the specialty-chemical / functional-additive tier. That is upstream of:

  • assay developers and diagnostics kit makers in Life Sciences;

  • electrode, separator and cell manufacturers in batteries.

It does not manufacture finished diagnostics or battery cells at commercial scale. For Ultranode, it supplies formulations and electrode samples and partners with cell makers and contract test centres such as the Battery Innovation Center in Indiana. Under the Airspeeder agreement (September 2026), it has stepped further downstream into cell design, but only at prototype scale and as consortium lead.

Customer types and end-markets

DivisionCustomer typesEnd-marketsGeographic focus (FY2026 commentary)
Life SciencesVaccine makers (QC assays), IVD kit manufacturers, point-of-care developers, CLIA/ELISA platform companies, research institutesIn-vitro diagnostics (lateral flow, ELISA, CLIA, biosensors), vaccine quality controlIndia (Serum Institute of India), USA, Europe, Japan (Cosmo Bio), South Korea (KOMA)
Advanced Battery TechnologiesAnode/electrode makers, separator makers, cell manufacturers, drone/UAS battery makers, eVTOL developers, consumer micro-battery makersHigh-silicon anodes, ceramic-coated separators, current-collector coatings, drones/defence, eVTOL, 3C electronics, micro-mobility, medical micro-batteriesUSA (Black Diamond Structures, two Ultranode 95 JDA negotiations, BIC), Europe (Wyon AG, Switzerland), South Korea (Xerabrid; battery distributor), Australia (Airspeeder)

Strategy

Stated strategy

The Strategic Review outcomes (10 June 2025) set four pillars:

  1. strategic direction and priorities;

  2. cost reductions and continuous improvement;

  3. strategic partnerships;

  4. risk management and governance.

The resulting strategy has five recurring themes:

Accelerate revenue generation: through clearer value propositions and more commercial relationship management.

  • Shift from bespoke R&D to standardised, market-ready products.

  • Expand the opportunity pipeline in fast-growing markets: e-mobility, drones/defence and life sciences, across India, Europe and the USA.

Build partnerships: to scale globally in a capital-light way.

  • Reduce costs, targeting net savings of A$1.6m a year.

The FY2026 webinar (30 Sep 2026) framed FY2027 as the "Sales Conversion" year, with a curated pipeline of qualified leads and samples under evaluation.

Strategic initiatives (last 24 months)

InitiativeDateDescriptionStatus
ARENA funding agreementOct 2024Up to A$4.0m for ABT developmentFirst milestone extended to November 2026
Queensland Critical Minerals & Battery Technology FundFY2025–FY2026Funding agreementCompany withdrew during FY2026
Strategic Review and restructureJun 2025Cost-out, organisational redesign, commercial focusImplemented. FY2026 cash opex A$6.86m vs A$8.45m in FY2025.
CRM and sales-system implementationFY2026Structured lead tracking (leads → MQL → SQL → samples)In place. Pipeline at 7 Sep 2026: LS 94 leads, 124 MQLs, 28 SQLs, 31 samples; ABT 22 leads, 51 MQLs, 29 SQLs, 32 samples.
Centralised global sales in Brisbane2,026Two sales and marketing personnel in Brisbane (Jan 2026)Ongoing
BDS JDSA (SiMRAX)Sep 2025US market entry for Anteo X plus carbon nanotubesSix customers trialling
Ultranode 95 drone/defence programme2025–2026BIC third-party validation; two US JDAsJDAs in negotiation; samples with two US drone battery makers
Wyon AG Ultranode 70Jun 2025 onwardConsumer and medical micro-battery evaluationOngoing
New product launchesFY2026Anteo S, Anteo C, SiMRAX ("three new offerings")Customer evaluations
Xerabrid SCSATerm sheet May 2026; binding Aug 2026Anteo S-enhanced separator solutionsCo-exhibiting at The Battery Show, Oct 2026
Airspeeder consortium leadSep 2026eVTOL prototype cell design and supplyCathode partner JDAs under negotiation
CLIA programme with global LS companyApr–Jul 2026AnteoBind NXT in chemiluminescence immunoassaysInitial stage complete; advancing
Distribution expansion2025–2026Cosmo Bio (Japan LS); South Korea ABT distributorExecuted
Capital raisingJan–Jun 2026A$3.81m placement; A$10.03m underwritten option exerciseComplete

Medium-term targets and guidance

AnteoTech provides no quantitative revenue, EBITDA or profitability guidance. Qualitative FY2027 priorities are:

  • converting customer evaluations into sales in India, the US, Europe, Japan and South Korea;

  • progressing CLIA and ELISA partnerships;

  • executing Ultranode 95 JDAs;

  • maintaining financial discipline.

ESG commitments: No formal emissions targets have been disclosed.

Products & Services

Advanced Battery Technologies

ProductDescriptionKey specifications / performance claimsTarget customerLaunch / statusPricing
Anteo X®Water-based, binder-compatible cross-linker for high-silicon lithium-ion anodes. Improves cohesion and mechanical stability through silicon's volume expansion.Improves cycle life and electrode integrity in silicon-containing anodes. Targets anodes with more than 15% silicon (BDS JDSA).Anode/electrode makers, cell makersCommercial; samples and early sales; multiple customer evaluations (2025–2026)—
Anteo S™Cross-linker for ceramic-coated separators (CCS)Improves ceramic coating adhesion and thermal/mechanical robustness. Being combined with Xerabrid separator designs.Separator makers, cell makersLaunched FY2026. Seven OEMs requested samples after the Xerabrid binding SCSA (August 2026, per StockWire X).—
Anteo CPrimer coating additive for current-collector foils (copper/aluminium)Improves electrode-to-foil adhesion. A 20L sample was shipped for South Korean scale trials.Electrode makers, foil makersLaunched and shipped for scale trials, June 2026; focus product at The Battery Show North America, October 2026—
SiMRAXJoint product: Anteo X + Black Diamond Structures' MOLECULAR REBAR® single-walled carbon nanotube dispersionMore than 50% higher cycle life in high-silicon anode cells at ultra-low nanotube loadings. Six companies trialling it (Sep 2026).US silicon-anode and cell makersFirst customer samples Q3 FY2026 (Mar quarter 2026); in customer trials—
Ultranode™ XHigh-silicon anode formulation for long-cycle applications1,020 cycles at 80% capacity retention (announced Dec 2025)Automotive EV, eVTOLDevelopment / validation—
Ultranode™ 70About 70% silicon anode formulationBalance of energy density and cycle life3C consumer electronics, micro-mobility, medical micro-batteries (Wyon AG)Under evaluation by Wyon AG (Switzerland) in commercial cell format since mid-2025—
Ultranode™ 9595% silicon anode formulation (integrated, "drop-in")1,800–2,400 mAh/g specific capacity (company). Independent BIC validation in a 5Ah multi-layer pouch: >390 Wh/kg cell specific energy; >300 cycles at 70% retention; about 40% energy-density uplift versus conventional cells (company claim).Drone/UAS/defence battery makers; eVTOL (Airspeeder)Validated May 2026. Two non-exclusive US JDAs in negotiation. Roll-to-roll coated electrode samples with two US drone battery makers.—
Cell-design servicesNext-generation cell chemistry design and prototype supplyConsortium lead roleAirspeeder (exclusive)Supply agreement September 2026—

Life Sciences

ProductDescriptionKey specifications / performance claimsTarget customerLaunch / statusPricing
AnteoBind™Surface-activation reagent that binds antibodies and proteins to diagnostic surfaces through coordination chemistryImproved sensitivity, reproducibility and orientation. Used by SII for vaccine quality-control assays.Vaccine makers, IVD kit makers, lateral-flow developersMature commercial product. SII five-year take-or-pay contract from July 2024 (about US$1.8m over 5 years).Contract-based; not publicly disclosed per unit
AnteoBind™ NXTNext-generation version for ELISA, CLIA and biosensorsUp to 6× lower capture-antibody usage versus conventional methods. Antibodies can be up to 35% of assay cost (company claim).CLIA/ELISA platform companies, IVD makersCommercial. CLIA kit launch planned. Activated ELISA plate prototype under SII evaluation.—
CLIA development programmeCollaborative product development with a large global life-sciences company (unnamed)Initial stage completed 1 July 2026; A$64,500 programme value; A$61,595 recognisedGlobal IVD companyAdvancing to next stageContract fee
Assay development / bioconjugation servicesContract services for assay developers—Point-of-care and diagnostics researchersOngoingFee-for-service

Legacy and discontinued offerings

OfferingStatus
Mix&Go™ (original nanoglue diagnostics reagent brand)Superseded by the AnteoBind branding
AnteoCoat™ (energy) and AnteoRelease™ (medical devices)Earlier development programmes; not current commercial focus
DIAsource ELISA/RIA assay catalogueDivested to BioVendor, 2017
SARS-CoV-2 Rapid Antigen TestDeveloped FY2021; no longer a reported revenue line

Financial Detail

Division Overview

DivisionContentsProducts and servicesLeadership

Advanced Battery Technologies (ABT)

Anode, separator and current-collector chemistry; anode formulations; cell-design services

Anteo X®, Anteo S™, Anteo C, SiMRAX (with BDS), Ultranode™ X / 70 / 95

Manuel Wieser, EGM – Advanced Battery Technology Business

Life Sciences (LS)

Antibody/protein immobilisation reagents; assay development services

AnteoBind™, AnteoBind™ NXT (incl. activated ELISA plate prototype, CLIA kit in development), contract assay development

—

Corporate

Finance, company secretarial, IR, sales operations (centralised in Brisbane from 2026)

—

Scott Waddell, CFO & Company Secretary

“—” = not publicly disclosed.

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2024FY2025FY2026

Revenue from customers (AUD Mn)

0.460.970.47

Total revenue and other income (AUD Mn)

4.353.463.13

Loss before tax (AUD Mn)

-8.88-6.76-5.38

Revenue growth YoY (%)

25.9110.4-51.7

Contribution to total revenue (%)

100100100

Revenue by Segment

MetricFY2025FY2026

Product sales (AUD Mn)

0.8850.403

Licence fees and royalties (AUD Mn)

0.0310.000

Contract services (AUD Mn)

0.0530.065

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Segment (%)

MetricFY2025FY2026

Revenue from largest single customer (% of external revenue)

81.059.0

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from customers (AUD Mn)

0.760.370.460.970.47

Revenue growth (%)

-15.3-51.925.9110.4-51.7

R&D tax concession and other income (AUD Mn)

1.513.223.782.432.60

Research expenses (AUD Mn)

5.765.846.273.883.02

SG&A / administration and selling (AUD Mn)

7.126.884.624.573.25

Asset write-down (AUD Mn)

0.002.220.000.000.00

Depreciation and amortisation (AUD Mn)

0.611.001.041.121.12

Share-based payments (AUD Mn)

1.200.830.930.640.52

EBITDA, derived (AUD Mn)

-10.05-11.69-7.85-5.63-4.23

Loss before tax (AUD Mn)

-10.72-12.65-8.88-6.76-5.38

Net loss (AUD Mn)

-10.72-12.65-8.88-6.76-5.38

Dividends per share (AUD)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Per-Share Data and Share Count (m)

MetricFY2025FY2026

Basic EPS (A cents)

-0.26-0.19

Diluted EPS (A cents)

-0.26-0.19

Weighted average shares (m)

2,613.62,842.1

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

EBITDA margin (%)

-1,322-3,159-1,707-581-905

Net margin (%)

-1,411-3,419-1,930-698-1,150

Income Statement

MetricFY2025FY2026

Administration expenses (AUD Mn)

3.852.56

Research expenses (AUD Mn)

3.883.02

Selling and distribution (AUD Mn)

0.640.70

Occupancy (AUD Mn)

0.080.13

Depreciation (AUD Mn)

1.121.12

Share-based payments (AUD Mn)

0.640.52

Directors' fees (AUD Mn)

0.3350.208

Professional services (AUD Mn)

0.670.34

Cash operating expenses excl. non-cash items, per company presentation (AUD Mn)

8.456.86

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Cash and equivalents (AUD Mn)

10.102.725.032.345.70

Short-term term deposit (AUD Mn)

0.000.000.000.005.50

Total current assets (AUD Mn)

10.833.145.452.7311.55

Total assets (AUD Mn)

15.265.369.386.4515.40

Lease liabilities, total (AUD Mn)

1.041.312.311.942.13

Borrowings / asset finance (AUD Mn)

0.000.000.020.020.01

Total debt incl. leases (AUD Mn)

1.031.312.331.962.15

Net cash incl. term deposit (AUD Mn)

9.071.412.690.389.05

Total liabilities (AUD Mn)

2.912.994.083.303.60

Shareholders' equity (AUD Mn)

12.362.385.313.1511.35

Goodwill and intangibles (AUD Mn)

00000

Working capital (AUD Mn)

9.211.343.661.4210.12

Contributed equity (AUD Mn)

87.4589.3099.82103.78116.83

Accumulated losses (AUD Mn)

-78.36-91.02-99.90-106.66-112.03

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (AUD Mn)

-8.69-8.08-6.52-5.83-3.53

Capital expenditure (AUD Mn)

-3.12-0.69-1.06-0.22-0.05

Free cash flow (AUD Mn)

-11.81-8.77-7.58-6.05-3.58

Gross equity issued (AUD Mn)

0.761.8511.484.3113.84

Lease principal repaid (AUD Mn)

-0.24-0.46-0.66-0.64-0.60

Dividends paid (AUD Mn)

00000

Share buybacks (AUD Mn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2023FY2024FY2025FY2026

ROE on average equity (%)

-172-231-160-74

ROA on average assets (%)

-123-120-85-49

Current ratio (x)

1.743.042.088.08

Debt / equity incl. leases (x)

0.550.440.620.19

Asset turnover (x)

0.040.060.120.04

Business Lines

LinePeakFY2026Change

Net loss

A$12.65m (FY2023, incl. A$2.22m write-down)

A$5.38m

-57%

Cash operating expenses

A$10.89m (FY2024)

A$6.86m

-37%

Free cash outflow

A$11.81m (FY2022)

A$3.58m

-70%

Region / Country Details

Region / countryEvidence of revenue activity (FY2025–FY2026)Indicative significance

India

Serum Institute of India five-year take-or-pay AnteoBind contract; largest customer was 81% (FY2025) and 59% (FY2026) of revenue

Very likely the largest revenue country (inferred, not disclosed)

Europe

CLIA development programme with a global life-sciences company (A$61,595 recognised FY2026); Wyon AG (Switzerland) Ultranode 70 evaluation

Contract-services revenue; Europe-based programme per webinar

USA

BDS JDSA/SiMRAX trials; BIC validation programme; two Ultranode 95 JDA negotiations; LS targets in POC, CLIA and ELISA

Pipeline; revenue not yet material

South Korea

KOMA (LS distributor since 2015); Xerabrid binding SCSA (Aug 2026); ABT distributor (Aug 2025); Anteo C trials

Pipeline / samples

Japan

Cosmo Bio appointed LS distributor (28 May 2026)

New channel; no revenue disclosed

Australia

Airspeeder supply agreement (Sep 2026); ARENA funding (grant, not revenue)

Prototype supply; immaterial revenue to date

Valuation Snapshot

MetricValueSource / date

Recent price

A$0.016

InvestSMART / MarketScreener, about 25–28 Sep 2026

52-week range

A$0.010 – A$0.049

Stocklight (mid-2026)

1-year performance

About -33% (A$0.024 on 3 Oct 2025 to about A$0.016)

StockAnalysis.com; analyst calculation

5-year average annual change

About -17.4% a year

Pearler (June 2026)

Notable single-day move

+30.8% on 21 May 2026 (Ultranode 95 validation)

Stocklight

Market Valuation

MetricJun 2026Aug 2026Sep 2026

Market capitalisation (AUD Mn)

885956

Valuation Multiples

MultipleAnteoTechComment

Market cap (AUD Mn)

About 52

Company cited A$56m at 23 Sep 2026

Enterprise value (AUD Mn)

About 43

Market cap 52 – cash and deposit 11.2 + leases and debt 2.15

EV/Sales (FY2026)

About 92x

A$43m / A$0.47m

P/B

About 4.6x

A$52m / A$11.35m equity

Balance Sheet and Share Count (m)

MetricFY2022FY2023FY2024FY2025FY2026

Gross equity raised (AUD Mn)

0.761.8511.484.3113.84

Shares on issue at year end (m)

1,9882,0502,4682,7053,260

Capital Markets

ItemWithin 12 monthsBeyond 12 monthsNotes

Asset finance

A$5,209

A$9,250

—

Lease liabilities

A$558,353

A$1,574,609

Brandl Street lease runs to 30 Nov 2029

Analyst Conclusions

Management guidance

No numerical guidance is given. Management's qualitative guidance (FY2026 webinar, 30 Sep 2026; Appendix 4E going-concern note) covers:

FY2027 as the "Sales Conversion" year: Convert 57 sales-qualified leads and 63 samples under evaluation into orders.

ABT: progress two Ultranode 95 drone JDAs in the US, Wyon's Ultranode 70 evaluation, SiMRAX customer trials, Anteo S/C/X conversion, and the Airspeeder consortium.

Life Sciences: progress CLIA and ELISA partnerships and expand with SII.

Financial discipline: continued cost control.

R&D refund: about A$1.9m to be booked in FY2027.

Consensus growth expectations: Not publicly disclosed.

Bull case

  1. Validated product meets an urgent market. Ultranode 95's independent BIC data (>390 Wh/kg in a commercial 5Ah cell) suits drone and defence buyers that value energy density over cycle life. Signed US JDAs could turn into supply volumes quickly. Amprius's 202% revenue growth to US$73m in CY2025 shows how fast this niche can scale.

  2. Several shots on goal with funded runway. A$11.2m in cash and deposits, an annual burn of about A$4–5m after R&D refunds, and roughly 7–8 commercial programmes (BDS/SiMRAX, Xerabrid/Anteo S, Wyon, Airspeeder, two Ultranode 95 JDAs, the CLIA partner, SII expansion). A single conversion could re-rate a A$50m-scale company.

  3. Operating leverage. With cash opex down 37% in two years to A$6.86m, incremental high-margin chemical sales flow largely to the bottom line. Life Sciences carries a credible cost-saving proposition (up to 6× less antibody) in a US$56bn IVD market.

Bear case

  1. History of non-conversion. After more than 25 years as a listed company and about A$117m of contributed equity, customer revenue is still below A$1m. FY2026 revenue fell 52%. JDAs "under negotiation" since early FY2026 remain unsigned.

  2. Concentration and fragility. 59% of revenue comes from one customer. The restatement after the preliminary results, the CFO turnover and a three-person board signal limited institutional infrastructure. Going-concern uncertainty persists.

  3. Competition and dilution. Silicon-anode competitors have balance sheets one to two orders of magnitude larger (Enovix about US$621m). Further raises at depressed prices remain likely before cash-flow breakeven: shares on issue are up 64% since FY2022, with 298m options outstanding.

Key catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
12–15 Oct 2026The Battery Show North America (Anteo S presentation, Xerabrid booth, SiMRAX customer meetings)
Oct 2026Q1 FY2027 Appendix 4C: customer receipts (incl. the A$134k SII shipment), cash burn
Nov 2026ARENA first-milestone deadline; AGM (remuneration votes, option packages)
16–19 Nov 2026MEDICA Düsseldorf (Life Sciences)
Nov 2026 onwardAirspeeder international race series; prototype cell progress
18 Dec 2026A$5.5m term deposit matures
FY2027 (any time)Execution of Ultranode 95 JDAs; SiMRAX purchase orders; CLIA stage-2 / supply agreement; Wyon commercial decision
Feb 2027H1 FY2027 results (revenue trajectory; receipt of the R&D refund of about A$1.9m)
OngoingPipeline metrics (SQLs → orders); new capital raisings; options exercised or lapsed

Analyst verdict

AnteoTech goes into FY2027 in a better financial position than at any time since FY2022. It has A$11.2m of cash and term deposits, negligible financial debt, and a cost base cut by more than a third in two years. Its core claims also now carry more credible external validation. The most material is the Battery Innovation Center's confirmation of Ultranode 95 performance in a commercial-format cell. The company has added three new battery products (Anteo S, Anteo C and SiMRAX) and binding partner agreements with Black Diamond Structures, Xerabrid and Airspeeder. With a structured sales pipeline of 57 qualified leads and 63 samples in evaluation, it has more simultaneous commercial options than at any point in its recent history.

The investment case, however, is still a commercialisation bet, not a business that can be valued on earnings. Customer revenue of A$0.47m in FY2026 covers under 7% of cash operating costs. More than half of it comes from one Indian customer under a contract worth about US$0.36m a year. The JDAs that would change the revenue profile remain unsigned after roughly a year of negotiation.

The restatement of the FY2026 loss after the preliminary results was non-cash and modest. Even so, together with a three-member board, a recently rebuilt finance function and continuing going-concern language, it argues for a governance discount. At an enterprise value of about A$43m (roughly 90x trailing sales), the market is already paying for partial conversion of the pipeline.

On balance, AnteoTech is a speculative, catalyst-driven holding. The single most important monitorable is the signing of at least one Ultranode 95 JDA, or a SiMRAX or CLIA supply contract with defined volumes, before mid-2027. Absent that, the cash runway will be spent on validation rather than revenue, and the next capital raising will set the valuation. With it, the company's reduced cost base gives meaningful operating leverage. The sensible stance today is neutral-to-speculative: technical and financial de-risking has clearly improved, but commercial proof is still outstanding.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenureBackgroundAge

Ms Glenda McLoughlin

Non-Executive Chair

Chair since 1 Apr 2025; director before that (appointment date not confirmed)

More than 20 years on listed company boards. Experience across energy, medical diagnostics, telecommunications, IT, media, transport and financial services.

—

Dr Geoffrey Cumming

Non-Executive Director

Joined 2009 as CEO; retired as CEO in 2016; now NED

Led Anteo from 2009, including the DIAsource acquisition and the associated fundraising. Co-chaired the Remuneration/Nomination Committee from April 2025.

—

Ms Merrill Gray

Managing Director & CEO

NED from January 2025 (sources differ: 15 Jan vs 31 Jan 2025); Interim MD/CEO from 16 Apr 2025; permanent MD/CEO from 19 Aug 2025

B.Sc, B.Min.Tech, MBA, MAusIMM, AFAIM. More than 30 years in mineral processing, the energy transition, and critical-minerals and battery-materials supply chains. Former ASX-listed MD/CEO.

60 (Simply Wall St)

“—” = not publicly disclosed.

Executive Leadership Team

NameTitleTenure / notes

Merrill Gray

MD & CEO

See above

Scott Waddell

Chief Financial Officer & Company Secretary

Interim CFO & CoSec from 2 Feb 2026; permanent appointment announced 17 Jul 2026

Manuel Wieser

Executive General Manager – Advanced Battery Technology Business

Presenting at The Battery Show North America, Oct 2026

Directors' Remuneration

MetricFY2025FY2026

Total directors' fees (AUD Mn)

0.3350.208

Board & Management Changes

DateChangeContext

1 Apr 2025

Glenda McLoughlin appointed Chair; two directors (incl. Katherine Woodthorpe AO) retire

Board renewal and cost reduction

16 Apr 2025

David Radford (CEO since Oct 2022) steps down; Merrill Gray Interim MD/CEO

Shift from R&D to commercialisation

1 May 2025

Director departure announced

Board downsizing

19 Aug 2025

Merrill Gray appointed permanent MD/CEO

Strategic Review execution

9 Jan 2026

CFO Andrew Cook resigns

—

2 Feb 2026

Scott Waddell Interim CFO & Company Secretary

—

17 Jul 2026

Scott Waddell confirmed as CFO & Company Secretary

—

Major Shareholders

RankHolderShares%
1

Marcolongo Nominees Pty Ltd

99,024,8693.04
2

First Cape Management Pty Ltd

55,195,5091.69
3

Citicorp Nominees Pty Limited

52,095,7351.60
4

AWO & CAO Investments Pty Ltd

48,900,0001.50
5

Addison Lake Quality Hire Pty Limited

38,844,8791.19
6

Mr Peter Frederick Kemmis

36,216,6761.11
7

BNP Paribas Nominees Pty Ltd

34,418,2261.06
8

Fossil Super Pty Ltd

33,920,0001.04
9

Mr Claus Kurt Dzalakowski

30,000,0000.92
10

Bond Street Custodians Limited

25,100,0000.77

Competitive Landscape

Competitors by Segment

AreaCompetitorTypeRelative positioning vs AnteoTech

Silicon anode (cells and materials)

Amprius Technologies (NYSE: AMPX)

Silicon-anode cell maker

Far larger. FY2025 revenue US$73.0m. Direct competitor in drone/UAS high-energy cells; also a potential customer archetype.

Silicon anode cells

Enovix (Nasdaq: ENVX)

3D silicon-anode cell maker

FY2025 revenue US$31.8m; R&D US$110.3m; about US$621m in cash and securities. Competes in defence and consumer segments.

Silicon anode materials

Group14 Technologies

Silicon-carbon composite supplier (private)

Scale materials supplier; financials not publicly disclosed

Silicon anode materials

Sila Nanotechnologies

Silicon anode material supplier (private)

Scale supplier; financials not publicly disclosed

Silicon anode materials

Nexeon (UK)

Silicon anode materials (private)

Financials not publicly disclosed

Silicon anode materials

NEO Battery Materials (TSXV: NBM)

Silicon anode developer

—

Anode materials (ASX peers)

Altech Batteries (ASX: ATC), Talga Group (ASX: TLG), Novonix (ASX: NVX)

ASX-listed anode-material developers

—

Binders / cross-linkers / CNT

Arkema, Syensqo (ex-Solvay), Zeon, Ashland (binders); OCSiAl (TUBALL SWCNT)

Large specialty chemical makers

Incumbent suppliers with scale; AnteoTech positions as a complementary additive

Diagnostics surface chemistry / conjugation

Thermo Fisher (Pierce), Merck KGaA/MilliporeSigma, Cytiva, Abcam (Lightning-Link), Bio-Techne

Global life-science tools makers

Dominant incumbents in conjugation and coupling reagents; AnteoTech competes on performance and antibody savings

Peer Comparison FY2025

MetricFY2024FY2025

AnteoTech revenue (AUD Mn, FY to June)

0.460.97

Amprius revenue (USD Mn, CY)

24.273.0

Enovix revenue (USD Mn, CY)

23.131.8

Peer Comparison FY2026

CompanyLatest FY revenue growth (%)R&D intensity (%)Cash / liquidity

AnteoTech (FY2026)

-51.7

647 (A$3.02m R&D / A$0.47m revenue)

A$11.2m cash plus term deposit

Amprius (CY2025)

202

12.9 (US$9.4m / US$73.0m)

US$91.9m cash

Enovix (CY2025)

38

347 (US$110.3m / US$31.8m)

About US$621m cash and securities

Recent Developments

--

Company Snapshot

40

Employees

1995

Founded

Eight Mile Plains, Australia

Headquarters

SWOT Analysis

Strengths

  • Funded balance sheet. Cash and term deposit of A$11.2m against total debt (mostly leases) of A$2.15m at 30 June 2026 (Appendix 4E FY2026).
  • Independent technical validation. Ultranode 95 achieved >390 Wh/kg and >300 cycles at 70% retention in a commercial-format 5Ah cell at the Battery Innovation Center (ASX, 21 May 2026).
  • Recurring contracted revenue. Five-year take-or-pay AnteoBind agreement with SII, about US$1.8m over 5 years from July 2024.
  • Demonstrated cost discipline. Cash operating expenses fell from A$10.89m (FY2024) to A$6.86m (FY2026), down 37% (FY2026 webinar).
  • Protected IP. 17 granted patents across a single cross-domain platform (FY2026 webinar).
  • Partner network spanning four countries. BDS (US), Wyon (Switzerland), Xerabrid (South Korea) and Airspeeder (Australia).
  • Non-dilutive funding access. R&D tax refunds of A$2.39m (FY2025) and A$2.59m (FY2026), plus ARENA funding of up to A$4.0m.

Weaknesses

  • Negligible revenue. A$467,589 in FY2026, down 52% and below 7% of cash opex (Appendix 4E FY2026).
  • Customer concentration. One customer provided 59% of FY2026 revenue (81% in FY2025) (Note 4).
  • Persistent losses. Accumulated losses of about A$112m against A$116.8m of contributed equity.
  • Going-concern material uncertainty remains in the FY2026 accounts.
  • Reporting-control flag. The A$447,580 post-release restatement of the FY2026 loss (16 Sep 2026) points to year-end close weaknesses at a small finance function. The CFO also changed in January 2026.
  • Thin governance bench. A three-person board limits committee independence. Key-person dependence on the MD/CEO.
  • No segment or geographic disclosure, which limits investor visibility.

Opportunities

  • Ultranode 95 JDAs. Two non-exclusive US drone/defence agreements under negotiation (FY2026 webinar).
  • SiMRAX. Six companies trialling, with sales forecasts being sought (StockWire X, Sep 2026).
  • CLIA partnership with a large global life-sciences company; first stage complete on 1 July 2026. CLIA is a high-value IVD segment.
  • eVTOL. Exclusive Airspeeder consortium-lead role in a market estimated at US$19bn (2026e).
  • Anteo S scaling. Seven OEMs requested samples after the Xerabrid binding agreement (Aug 2026).
  • Expansion of the SII relationship through AnteoBind NXT activated ELISA plates (under evaluation).
  • Pipeline depth. 57 sales-qualified leads and 63 samples under evaluation (7 Sep 2026).

Threats

  • Well-capitalised competitors. Enovix holds about US$621m of liquidity; Amprius has US$73m of revenue and is scaling in the same drone segment.
  • Dilution risk if conversion is slow. Shares on issue are up 64% since FY2022; 298m options outstanding.
  • Funding milestone risk. The ARENA first milestone was already extended to November 2026, and the company withdrew from the Queensland fund agreement.
  • Long qualification cycles in batteries. Wyon's evaluation has been running since June 2025 without a commercial order disclosed.
  • Partner dependency. Revenue relies on partners' commercial timelines (e.g. Vidcare's revised timelines).
  • Share-price volatility. 52-week range A$0.01–0.049; market cap moved from A$88m (Jun 2026) to about A$52–56m (Sep 2026). This affects the terms of future raisings.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
1 Apr 2025Glenda McLoughlin appointed Non-Executive Chair; two directors retireBoard renewal and cost reduction
16 Apr 2025CEO David Radford steps down; Merrill Gray Interim MD/CEOLeadership reset toward commercialisation
1 May 2025Director departure and shareholding updateBoard shrinks
10 Jun 2025Strategic Review outcomes: A$1.6m a year net savings; restructure; commercial focusFoundation of the current strategy
Jun 2025Wyon AG begins Ultranode trials for potential commercial useFirst European cell-maker evaluation
30 Jul 2025Q4 FY2025 4C: BDS binding term sheet; significant SII order; cash A$2.7m; pro-forma A$5.3m incl. R&D refundLiquidity stretched before raises
11 Aug 2025South Korean battery distributor appointedABT channel
19 Aug 2025Merrill Gray appointed permanent MD/CEO; 22.15m STI shares issued to staffLeadership stability
27–28 Aug 2025FY2025 results: net loss A$6.76m; revenue A$0.97mRevenue doubled on the SII contract
25 Sep 2025JDSA executed with Black Diamond StructuresUS market-entry vehicle
Oct 2025Management visit to BDS (Texas); attendance at The Battery Show, DetroitUS business development
27 Oct 2025Q1 FY2026 4C: CRM in place; CSIRO agreement; India LS focusCommercial infrastructure
26 Nov 2025AGM; CEO and NED option packages approved; remuneration report carriedGovernance
Dec 2025Ultranode X exceeds 1,000 cycles at 80% capacity retentionTechnical milestone for EV/eVTOL
Dec 2025 – Jan 2026US$185k AnteoBind order from SII (paid 5 Jan 2026)Recurring LS revenue
9 Jan 2026CFO Andrew Cook resignsFinance leadership change
19 Jan 2026ABT update: two non-exclusive Ultranode 95 JDAs in negotiation; Wyon progressingDrone market traction
22–27 Jan 2026Trading halt; A$3.5m capital raising (placement at A$0.0155 with attaching options)Runway extension
30 Jan 2026Q2 FY2026 4C: cash A$1.4m before raise; no debt; BDS SiMRAX trials scheduled for Feb 2026Low point in liquidity
2 Feb 2026Scott Waddell appointed Interim CFO & Company Secretary—
Feb 2026Attendance at BioAsia, IndiaLS business development
25 Feb 2026Half-year report: loss A$1.40m (down 36%); R&D refund A$2.59m receivedCost reset visible
2 Mar 2026Half-year investor webinar—
26 Mar 2026Presentation at NWR Virtual Healthcare ConferenceInvestor outreach
20 Apr 2026Q3 FY2026 4C: cash A$3.291m; record samples dispatched; first SiMRAX customer samples; new CLIA programme (A$64.5k)Pipeline build
8 May 2026Investor presentation ("cash-rich, debt-free")—
21 May 2026Ultranode 95 validated at BIC in 5Ah commercial-format cell; shares +30.8% on the dayKey technical de-risking
26 May 2026Xerabrid Strategic Collaboration and Sales Agreement term sheet (Anteo S)Korean separator partnership
28 May 2026Japan Life Sciences distributor appointed (Cosmo Bio)Japan market entry
29 May 2026MST Financial underwrites exercise of ADOO options (minimum A$7.5m)Funding certainty
2–5 Jun 2026286.6m options exercised, raising A$10.03mBalance-sheet repair
11 Jun 2026Gold Coast Investment Showcase presentation; market cap A$88m at 9 Jun 2026Peak valuation period
Jun 2026Anteo C launched; 20L sample shipped for South Korean scale trialsNew ABT product
1 Jul 2026CLIA programme completed; relationship advancesFirst LS income from the global partner
7 Jul 2026A$134,138 SII shipment (FY2027 revenue)Recurring revenue
17 Jul 2026Scott Waddell confirmed as CFO & Company SecretaryFinance stability
20 Jul 2026Q4 FY2026 4C: cash A$11.2m; quarterly operating outflow A$1.585m; customer receipts A$17kLiquidity strong; sales still minimal
Aug 2026Xerabrid binding SCSA; seven OEMs request samplesPartnership formalised
24 Aug 2026Life Sciences pipeline roughly tripled after ADLM 2026 (StockWire X)LS pipeline growth
26 Aug 2026Updated Securities Trading Policy adoptedGovernance
31 Aug 2026Appendix 4E: revenue A$0.47m (-52%); loss A$4.93m (unaudited)Annual results
c. 8 Sep 2026Exclusive Airspeeder supply agreement; Team Australia battery consortium leadeVTOL showcase
16 Sep 2026Update to Appendix 4E: loss restated to A$5.38m (non-cash make-good adjustment)Reporting-quality flag
18 Sep 20262026 AGM date noticeGovernance calendar
28 Sep 2026FY2026 Annual Report lodgedAudited accounts
30 Sep 2026FY2026 results webinar: FY2027 "sales conversion" year; 17 granted patents; FY2026 R&D refund of about A$1.9m to be booked in FY2027Strategic framing
6 Oct 2026NIPER India technical webinar (lateral flow / paper diagnostics)LS India business development
12–15 Oct 2026 (upcoming)The Battery Show North America, Detroit (Austrade delegation): Anteo S presentation; Xerabrid booth; SiMRAX customersABT catalyst
16–19 Nov 2026 (upcoming)MEDICA, DüsseldorfLS catalyst
Nov 2026 (upcoming)ARENA first-milestone deadline (extended)Funding catalyst / risk

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue from customers fell from AUD 0.8 Mn in FY2022 to AUD 0.5 Mn in FY2026.
AnteoTech Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from customers0.80.40.510.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. AnteoTech Ltd, Appendix 4E Preliminary Final Report FY2026 (unaudited), ASX, 31 Aug 2026.
  2. AnteoTech Ltd, Update to Appendix 4E – Preliminary Final Report, ASX, 16 Sep 2026.
  3. AnteoTech Ltd, Annual Report to shareholders FY2026, ASX, 28 Sep 2026 (referenced).
  4. AnteoTech Ltd, FY2026 Results Investor Webinar / Presentation, 30 Sep 2026 (via StockWire X and Quartr summaries).
  5. AnteoTech Ltd, Appendix 4C quarterly reports: 30 Jul 2025, 27 Oct 2025, 30 Jan 2026, 20 Apr 2026, 20 Jul 2026.
  6. AnteoTech Ltd, Half-Year Report to 31 Dec 2025, ASX, 25 Feb 2026; H1 FY2026 Investor Briefing, 2 Mar 2026.
  7. AnteoTech Ltd ASX announcements
  8. Appointment of Non-Executive Chair (1 Apr 2025)
  9. Appointment of Interim CEO (15 Apr 2025)
  10. Strategic Review Outcomes (10 Jun 2025)
  11. Appointment of MD & CEO (19 Aug 2025)
  12. JDSA executed (25 Sep 2025)
  13. AGM results (26 Nov 2025)
  14. CFO resignation (9 Jan 2026)
  15. ABT update (19 Jan 2026)
  16. Trading halt (22 Jan 2026)
  17. Ultranode 95 validation (21 May 2026)
  18. Underwriting (29 May 2026)
  19. CFO appointment (17 Jul 2026)
  20. Securities Trading Policy (26 Aug 2026)
  21. Airspeeder supply agreement (Sep 2026)
  22. AnteoTech / Anteo Diagnostics Annual Reports FY2019–FY2021 and Appendix 4E filings (ASX).
  23. S&P Global Market Intelligence data via StockAnalysis.com (income statement, balance sheet, cash flow, FY2021–FY2026), accessed Sep–Oct 2026.
  24. InvestSMART, Market Index, Stocklight, Pearler and MarketScreener (prices, announcement registers, director trades).
  25. PitchBook company profile (founding year, former names, headcount); Simply Wall St (CEO profile, compensation, analyst count).
  26. PR Newswire / BioSpace (26 Aug 2015; 10 Oct 2017), Australian Manufacturing (2016) and Clinical Lab International (2017): DIAsource acquisition and divestiture.
  27. Amprius Technologies FY2025 results (8-K, 4 Mar 2026; 10-K FY2025); Enovix FY2025 results (press release, 25 Feb 2026; 10-K FY2025).
  28. StockWire X articles (Jul–Sep 2026) and SmallCaps (2026) for event summaries; figures cross-checked against ASX filings where possible.

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.